[ DIATRIZOATE MEGLUMINE AND
DIATRIZOATE SODIUM INJECTION U.S.P.]
MD-76R (Diatrizoate Meglumine and Diatrizoate Sodium Injection USP) is a radiopaque contrast agent supplied as a sterile, aqueous solution. Intended for intravascular administration, MD-76R contains 66% w/v 1-deoxy-1-(methylamino)-D-glucitol 3,5-diacetamido-2,4,6, triiodobenzoate (salt) and 10% w/v monosodium 3,5-diacetamido-2,4,6, triiodobenzoate.
MD-76R is indicated in excretion urography, aortography, pediatric angiocardiography, peripheral arteriography, selective renal arteriography, selective visceral arteriography, selective coronary arteriography with or without left ventriculography, contrast enhancement of computed tomographic brain imaging and for intravenous digital subtraction angiography.
MD-76R is also indicated for the contrast enhancement in body computed tomography. (See Clinical Pharmacology). Continuous or multiple scans separated by intervals of 1-3 seconds during the first 30-90 seconds post-injection of the contrast medium (dynamic CT scanning) provide enhancement of diagnostic significance. Subsets of patients in whom delayed body CT scans might be helpful have not been identified. Inconsistent results have been reported and abnormal and normal tissues may be isodense during the time frame used for delayed CT scanning. The risks of such indiscriminate use of contrast media are well known and such use is not recommended. At present, consistent results have been documented using dynamic CT techniques only.
Media Articles Related to MD-76R (Diatrizoic Acid / Diatrizoic Acid)
A Diagnostic Challenge: When Fibromyalgia Coexists with AS (CME/CE)
Source: MedPageToday.com - medical news plus CME for physicians [2017.01.13]
(MedPage Today) -- Prevalence of 43% among AS patients found in new study
New diagnostic test kit offers easy identification of virulent pathogens in remote locations
Source: Medical Devices / Diagnostics News From Medical News Today [2016.12.22]
A team of researchers has developed a portable detection system that can rapidly identify some of the most virulent, often multi-drug resistant pathogens.
Flexible future of point-of-care disease diagnostic
Source: Bird Flu / Avian Flu News From Medical News Today [2015.07.29]
The world-wide deployment of biomedical devices for health monitoring, point-of-care diagnostics and environmental sensing is hampered by their high cost that is not readily affordable for e.g.
New Imaging Approach the Future of TIA Diagnosis?
Source: Medscape Critical Care Headlines [2017.01.12]
A new understanding of processes involved in inflammation of the cerebral blood vessels during a transient ischemic attack may eventually lead to a new diagnostic test for patients with this condition.
Medscape Medical News
Colon Ischemia: Don't Miss This
Source: Medscape Family Medicine Headlines [2017.01.10]
Dr David Johnson reviews the optimal diagnostic and treatment strategies for ischemic colitis, particularly isolated right-sided colon ischemia, a disease not to be missed.
Published Studies Related to MD-76R (Diatrizoic Acid / Diatrizoic Acid)
Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent. [2010.05.31]
Aerosolized contrast agents may improve the resolution of biomedical imaging modalities and enable more accurate diagnosis of lung diseases. Many iodinated compounds, such as diatrizoic acid, have been shown to be safe and useful for radiographic examination of the airways...
Powdered diatrizoic acid for radiography of the respiratory tract. Part II. Clinical application. [1991.11]
The diagnostic and clinical value of 41 examinations using insufflation and/or inhalation of powdered diatrizoic acid for tracheobronchography, tracheography, laryngography, nasopharyngography, and sinusography was investigated in 35 patients. Diatrizoic acid was found to be useful when applied by insufflation for demonstration of the nasopharynx, trachea and greater bronchi, especially in patients with airway stenosis and low pulmonary reserve...
Powdered diatrizoic acid for radiography of the respiratory tract. Part I. Experimental investigation. [1991.09]
Powdered diatrizoic acid as a contrast medium administered by inhalation and insufflation for visualization of the airways was tested in vitro and in 21 dogs. Good radiopacity of the contrast medium and its antibacterial activity was found in vitro... Histologic and ultrastructural examinations after contrast studies showed phagocytic reaction to diatrizoic acid, transient impairment of production of surfactant, reactive changes of bronchial mucosa, and no fibrotic changes in the long-term observation.
Page last updated: 2017-01-13